ALG 097558
Alternative Names: ALG-097558; Coronavirus therapeutic - Aligos Therapeutics/Centre for Drug Design and Discovery/Rega Institute for Medical ResearchLatest Information Update: 23 Apr 2026
At a glance
- Originator Aligos Therapeutics; Centre for Drug Design and Discovery; Rega Institute for Medical Research
- Developer Aligos Therapeutics; University of Liverpool
- Class Alkanes; Amides; Antivirals; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Isoindoles; Nitriles; Pyrrolidinones; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 23 Apr 2026 Chemical structure information added
- 31 Dec 2025 Aligos Therapeutics has multiple patents for ALG 097558 directed o compositions of matter and method of use for ALG 097558 before December 2025
- 28 Jul 2025 Aligos Therapeutics completes a phase I trial in COVID-2019 infections in USA (PO) (NCT06568861)